000661，爆雷！

Core Viewpoint - Changchun High-tech's financial performance has significantly declined, with both revenue and net profit showing substantial decreases in 2024 and the first quarter of 2025 [4][6][10]. Financial Performance Summary - In 2024, Changchun High-tech reported revenue of 13.47 billion yuan, a decrease of 7.6% year-on-year, and a net profit attributable to shareholders of 2.58 billion yuan, down 43% from the previous year [6][7]. - The fourth quarter of 2024 saw a revenue drop to 3.08 billion yuan, a decline of 20.8% year-on-year, with a net profit loss of 206 million yuan, a decrease of 122.4% [7]. - For the first quarter of 2025, the company achieved revenue of 2.99 billion yuan, down 5.66% year-on-year, and a net profit of 472 million yuan, a decrease of 44.95% [9][10]. Subsidiary Performance - Jinsai Pharmaceutical, the core subsidiary of Changchun High-tech, reported a revenue of 10.67 billion yuan in 2024, a decrease of 3.73%, and a net profit of 2.68 billion yuan, down 40.67% [10]. - In the first quarter of 2025, Jinsai Pharmaceutical's revenue was 2.62 billion yuan, an increase of 5.94%, but its net profit decreased by 38.31% to 535 million yuan [10]. Shareholder Information - As of March 31, 2025, Changchun High-tech had a total of 125,097 shareholders, reflecting a decrease of 1.80% from the previous quarter [11].